Tele: 561.316.3330
Breaking Medical Device News

Tuesday, September 21, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeClinical Trials, Studies, Data UpdatesAppend Medical Completes In-Vivo Pre-clinical Chronic Procedures for Stroke Reduction

Append Medical Completes In-Vivo Pre-clinical Chronic Procedures for Stroke Reduction

Append Medical

Append Medical, developer of the Appligator™, a novel implant-free left atrial appendage (LAA) exclusion device, today announced completion of its first ever pre-clinical chronic procedure.

Append Medical notes the procedures were completed with IMMR, one of the world’s leading preclinical laboratories and paves the way for the first human trial.

Append’s team was granted special permission to enter France by its Ministry of the Interior based on the promise its technology holds for stroke prevention in atrial fibrillation patients, a major global health concern.

“These first procedures provide an important validation for our approach, which is intended to significantly simplify the goal of sealing the LAA and preventing stroke in AF patients without leaving any implant in the heart,” said Zachi Berger, PhD, Founder and CEO of Append Medical. “Organizing this trial during the current pandemic was not a simple task and we would like to thank the relevant French bodies as well as the IMMR team for allowing us to complete this trial while complying with COVID-19 restrictions.”

Append Medical
After procedure completed

“My team and I found the procedure to be elegant and straightforward toward continuing to make LAA exclusion more accessible,” said Dr. Nicolas Borenstein, DVM, PhD. Scientific and Technical Director at IMMR. Both animals are doing fine so far, and the post-procedure images are spectacular. Congratulations to the Append team on this achievement.”

The Append Medical “Appligator™” is designed to reduce stroke risk in AF patients by excluding the LAA to prevent blood clot leakage with a minimally invasive transseptal intervention leaving no implant behind. The Appligator device utilizes natural tissue manipulation to achieve complete LAA closure through invagination of the LAA into

the left atrium. This approach is designed to minimize device-related thromboembolism risk by leaving only a suture – and no metal implant – at the closure site.

Append Medical operates as part of MEDX Xelerator in Israel. MEDX Xelerator’s partners include MEDX Ventures, Boston Scientific Inc., Intellectual Ventures and Sheba Medical Center.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

FDA Authorizes Software that Can Help Identify Prostate Cancer

The software is called Paige Prostate and is compatible for use with slide images that have been digitized using a scanner.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

By using this website you agree to accept Medical Device News Magazine Privacy Policy